Results 151 to 160 of about 212,526 (280)

Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis: an open-label, phase 2 trial [PDF]

, 2023
Ragha Suresh, Collin Dunnam, Dhananjay Vaidya, R.J.K. Wood, Bruce S. Bochner, Donald W. MacGlashan, Melanie C. Dispenza   +6 more
openalex   +1 more source

Primary immunodeficiency in Hong Kong and the use of genetic analysis for diagnosis [PDF]

, 2005
Objectives. To review the management of primary immunodeficiency and discuss recent advances in genetic analysis. Design. Retrospective study. Setting. University teaching hospital, Hong Kong. Patients.
Chan, KW, Ho, HK, Lam, DST, Lau, YL, Lee, TL   +4 more
core  

Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease

Journal of Neuroimmune Pharmacology, 2019
Bruton’s tyrosine kinase (BTK), a critical component of B cell receptor signaling, has recently been implicated in regulation of the peripheral innate immune response. However, the role of BTK in microglia, the resident innate immune cells of the central
J. Keaney, Julien Gasser, Gaëlle Gillet, D. Scholz, Irena Kadiu   +4 more
semanticscholar   +1 more source

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Brain and Behavior, Volume 16, Issue 5, May 2026.
Chronic inflammatory demyelinating polyneuropathy is an autoimmune disorder causing demyelination, leading to distal weakness, sensory loss, and autonomic dysfunction. Immune activation triggers macrophage‐mediated myelin damage and conduction failure.
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
wiley   +1 more source

Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐CHOP

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background A number of studies have demonstrated the important role of activation‐induced cytidine deaminase (AID) in the pathogenesis of diffuse large B‐cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.
Mardiah Suci Hardianti, Nungki Anggorowati, Syahru Agung Setiawan, Miraz Radhea Bagaskoro, Johan Kurnianda, Kartika Widayati Taroeno‐Hariadi, Ibnu Purwanto, Susanna Hilda Hutajulu   +7 more
wiley   +1 more source

A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton’s Tyrosine Kinase Inhibitor CC-292 [PDF]

, 2021
Matt Labenski, Lukas Voortman, Aravind Medikonda, Philip J. Sherratt, Alan F. Corin   +4 more
openalex   +1 more source

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Recent clinical trials have underscored the value of repeated minimal residual disease (MRD) measurements as a highly sensitive method for detecting subclinical disease and enabling dynamic risk stratification in hematologic malignancies. Despite its clinical potential, the complex and heterogeneous nature of MRD kinetics presents significant ...
Francesca Cordero, Simone Ferrero, Simone Pernice, Elisa Genuardi, Daniela Volpatto, Roberta Sirovich, Aurora Maria Civita, Andrea Evangelista, Simone Ragaini, Alice Di Rocco, Alessandro Re, Vittorio Stefoni, Federica Cavallo, Carola Boccomini, Monica Balzarotti, Vittorio Ruggero Zilioli, Maria Gomes da Silva, Luca Arcaini, Melania Celli, Gian Maria Zaccaria, Dora Tortarolo, Marco Beccuti, Eva Hoster, Christiane Pott, Elizabeth Macintyre, Olivier Hermine, Martin Dreyling, Marco Ladetto   +27 more
wiley   +1 more source

Function of Bruton's tyrosine kinase during B cell development is partially independent of its catalytic activity [PDF]

, 2003
The Tec family member Bruton's tyrosine kinase (Btk) is a cytoplasmic protein tyrosine kinase that transduces signals from the pre-B and B cell receptor (BCR).
Dahlenborg, K., Dingjan, G.M. (Gemma), Hendriks, R.W. (Rudi), Maas, A. (Alex), Middendorp, S.   +4 more
core   +1 more source

Population Pharmacokinetic Modeling and Exposure‐Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor under clinical investigation in patients with hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Nemtabrutinib plasma concentration data from 578 patients enrolled in phase 1 and 2 clinical studies, treated with doses from 5 to ...
Chiara C. Kemal, Thijs J. Zweers, Elke H. J. Krekels, Manash S. Chatterjee   +3 more
wiley   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, Volume 183, Issue 10, Page 2446-2463, May 2026.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source